Skip to main content

Facial Lipoatrophy

0
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Croma-Pharma
Croma-PharmaAustria - Leobendorf
2 programs
Princess® FILLERN/A1 trial
Princess® VOLUMEN/A1 trial
Active Trials
NCT03050723Completed53Est. Jan 2018
NCT03050749Completed56Est. Mar 2018
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
1 program
SCULPTRAN/A1 trial
Active Trials
NCT00360932Completed290Est. Aug 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Croma-PharmaPrincess® VOLUME
Croma-PharmaPrincess® FILLER
Bausch HealthSCULPTRA

Clinical Trials (3)

Total enrollment: 399 patients across 3 trials

NCT03050749Croma-PharmaPrincess® VOLUME

Safety and Performance of Princess® VOLUME for the Treatment of Facial Lipoatrophy, Asymmetry or Scars

Start: Nov 2016Est. completion: Mar 201856 patients
N/ACompleted
NCT03050723Croma-PharmaPrincess® FILLER

Safety and Performance of Princess® FILLER for the Treatment of Facial Lipoatrophy, Asymmetry or Scars

Start: Nov 2016Est. completion: Jan 201853 patients
N/ACompleted

Facial Lipoatrophy Correction Experience With SCULPTRA ("FACES" Study)

Start: Oct 2005Est. completion: Aug 2011290 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.